Even in normal times, mass-vaccination campaigns have many moving parts within a vast network of suppliers, transporters, and middlemen.
The details of Pfizer’s vaccine will make this effort more complicated. Vaccine, developed With the German company BioNTech, Should be stored around minus 70 ° C (minus 94 Fahrenheit) until shortly before injection. It is about the temperature of the South Pole on a winter day And more chills development than any other vaccine.
Pending results from other front-runners in the vaccine race may change the stakes. Modern medical science On Wednesday, it said it had seen enough Kovid-19 cases in its late-stage study to perform an initial analysis of its vaccine, which uses Pfizer’s “messenger RNA” technology. Technology has never produced approved vaccines.
Nine other candidates Are also in the final stages of testing. If any of them receive approval from the FDA, it would reduce the importance of Pfizer’s vaccines, but would also present new questions, such as hospitals and people receiving different vaccines.
For now, however, Pfizer is in the headlines.
If the planned analysis for the next week confirms the vaccine’s safety, the company is likely to ask the FDA for emergency authorization to distribute its vaccine this month. In that case, limited doses would most likely be sent to larger hospitals and pharmacies to provide health care workers and other vulnerable groups.
But it is best in specifics of how it will work.
Pfizer does not yet know where the government wants the vaccine to be sent or who will be in the first line to receive it, said Ms. Alcorn, a supply chain executive.
Referring to the federal initiative for the production and distribution of Kovid-19 vaccines, Ms. Alcorn said, “In the US, especially with Operation Tana Speed, we are working very closely.” “They don’t have it today.”